The overvaluation of CD4+ T-cell mediated inflammation as primary therapy target: The current EAE-inspired research focus on the immune system seems to disregard the strong neurodegenerative component in MS, which is particularly pronounced in the progressive phase but is already present at disease onset [28]. The gene discussed is CD4; the disease is myeloid sarcoma.